Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 197 articles:
HTML format
Text format



Single Articles


    October 2019
  1. RESTREPO DJ, Boczar D, Huayllani MT, Sisti A, et al
    Survival Disparities in Male Patients With Breast Cancer.
    Anticancer Res. 2019;39:5669-5674.
    PubMed     Text format     Abstract available


  2. OZAWA H, Sata A, Fukui R, Bun A, et al
    A Single-centre, Retrospective, Observational Analysis of Fulvestrant for Recurrent/metastatic Breast Cancer According to Metastatic Site.
    Anticancer Res. 2019;39:5653-5662.
    PubMed     Text format     Abstract available


  3. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Clinical Evaluation of Dynamic Monitoring of Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratios in Primary Endocrine Therapy for Advanced Breast Cancer.
    Anticancer Res. 2019;39:5581-5588.
    PubMed     Text format     Abstract available


  4. MORGAN S, Amemiya Y, Slodkowska E, Lu FI, et al
    Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients.
    Anticancer Res. 2019;39:5345-5352.
    PubMed     Text format     Abstract available


  5. DAMASKOS C, Garmpi A, Nikolettos K, Vavourakis M, et al
    Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
    Anticancer Res. 2019;39:5285-5296.
    PubMed     Text format     Abstract available


  6. CANALE ML, Camerini A, Huqi A, Lilli A, et al
    Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity.
    Anticancer Res. 2019;39:5741-5745.
    PubMed     Text format     Abstract available


  7. SUSINI T, Renda I, Giani M, Vallario A, et al
    Changing Trends in Mastectomy and Breast Reconstruction. Analysis of a Single-institution Experience Between 2004-2016.
    Anticancer Res. 2019;39:5709-5714.
    PubMed     Text format     Abstract available


  8. WOO HY, DO SI, Kim SH, Song SY, et al
    Promoter Methylation Down-regulates B-cell Translocation Gene 1 Expression in Breast Carcinoma.
    Anticancer Res. 2019;39:5361-5367.
    PubMed     Text format     Abstract available


    September 2019
  9. GOMES I, Aguiar P, Miranda A, Nunes C, et al
    Overall Survival of Patients With Locoregional and Metastatic Breast Cancer: Is the Influence of Baseline Characteristics the Same?
    Anticancer Res. 2019;39:5135-5142.
    PubMed     Text format     Abstract available


  10. INOUE N, Li W, Fujimoto Y, Matsushita Y, et al
    High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer.
    Anticancer Res. 2019;39:5009-5018.
    PubMed     Text format     Abstract available


  11. LEWIN NL, Luetragoon T, Shamoun L, Oliva D, et al
    The Influence of Adjuvant Radiotherapy and Single Nucleotide Polymorphisms on Circulating Immune Response Cell Numbers and Phenotypes of Patients With Breast Cancer.
    Anticancer Res. 2019;39:4957-4963.
    PubMed     Text format     Abstract available


  12. RESTREPO DJ, Sisti A, Boczar D, Huayllani MT, et al
    Characteristics of Breast Cancer Patients Who Refuse Surgery.
    Anticancer Res. 2019;39:4941-4945.
    PubMed     Text format     Abstract available


  13. NASIOUDIS D, Wilson E, Mastroyannis SA, Sisti G, et al
    Increased Risk of Breast and Uterine Cancer Among Women With Ovarian Granulosa Cell Tumors.
    Anticancer Res. 2019;39:4971-4975.
    PubMed     Text format     Abstract available


  14. HUNAKOVA L, Horvathova E, Gronesova P, Bobal P, et al
    Triorganotin Isothiocyanates Affect Migration and Immune Check-point Receptors in Human Triple-negative Breast Carcinoma MDA-MB-231 Cells.
    Anticancer Res. 2019;39:4845-4851.
    PubMed     Text format     Abstract available


    August 2019
  15. CHO O, Chun M, Kim SW, Jung YS, et al
    Lymphopenia as a Potential Predictor of Ipsilateral Breast Tumor Recurrence in Early Breast Cancer.
    Anticancer Res. 2019;39:4467-4474.
    PubMed     Text format     Abstract available


  16. SEDLOEV T, Vlahova A, Usheva S, Vasileva-Slaveva M, et al
    Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.
    Anticancer Res. 2019;39:4393-4398.
    PubMed     Text format     Abstract available


  17. TUOHINEN SS, Skytta T, Huhtala H, Virtanen V, et al
    Left Ventricular Speckle Tracking Echocardiography Changes Among Early-stage Breast Cancer Patients Three Years After Radiotherapy.
    Anticancer Res. 2019;39:4227-4236.
    PubMed     Text format     Abstract available


  18. KOLBERG HC, Uhl V, Massarut S, Holmes D, et al
    Targeted Intraoperative Radiotherapy During Breast-conserving Surgery for Breast Cancer in Patients After Implant Augmentation.
    Anticancer Res. 2019;39:4215-4218.
    PubMed     Text format     Abstract available


  19. MENDONCA P, Darwish AG, Tsolova V, El-Sharkawy I, et al
    The Anticancer and Antioxidant Effects of Muscadine Grape Extracts on Racially Different Triple-negative Breast Cancer Cells.
    Anticancer Res. 2019;39:4043-4053.
    PubMed     Text format     Abstract available


  20. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
    Anticancer Res. 2019;39:4031-4041.
    PubMed     Text format     Abstract available


  21. NISHIMURA M, Onoe T, Sakai H, Arase M, et al
    Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.
    Anticancer Res. 2019;39:4379-4383.
    PubMed     Text format     Abstract available


  22. HAYASHI M, Nakazawa K, Hasegawa Y, Horiguchi J, et al
    Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.
    Anticancer Res. 2019;39:4305-4314.
    PubMed     Text format     Abstract available


  23. YUE CH, Liu JY, Chi CS, Hu CW, et al
    Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERalpha Signaling Pathway in High-level MZF1-expressing TNBC cells.
    Anticancer Res. 2019;39:4149-4164.
    PubMed     Text format     Abstract available


    July 2019
  24. SHIMADA K, Ishikawa T, Yamada A, Sugae S, et al
    Matrix-producing Carcinoma as an Aggressive Triple-negative Breast Cancer: Clinicopathological Features and Response to Neoadjuvant Chemotherapy.
    Anticancer Res. 2019;39:3863-3869.
    PubMed     Text format     Abstract available


  25. CSONKA A, Kincses A, Nove M, Vadas Z, et al
    Selenoesters and Selenoanhydrides as Novel Agents Against Resistant Breast Cancer.
    Anticancer Res. 2019;39:3777-3783.
    PubMed     Text format     Abstract available


  26. STRAVODIMOU A, Voutsadakis IA
    A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer.
    Anticancer Res. 2019;39:3295-3301.
    PubMed     Text format     Abstract available


    June 2019
  27. SUSINI T, Carriero C, Tani F, Mattioli G, et al
    Day Surgery Management of Early Breast Cancer: Feasibility and Psychological Outcomes.
    Anticancer Res. 2019;39:3141-3146.
    PubMed     Text format     Abstract available


  28. PARK JH, Lee HJ, Lee SB, Ahn JH, et al
    Intrinsic Prognostic Impact of Tumor-infiltrating Lymphocytes in Systemically Untreated Patients With Early-stage Triple-negative Breast Cancer.
    Anticancer Res. 2019;39:3111-3119.
    PubMed     Text format     Abstract available


  29. TAKADA K, Kashiwagi S, Asano Y, Goto W, et al
    Prognostic Value of Quality of Life in Endocrine Therapy for Elderly Patients With Breast Cancer: A Retrospective Study.
    Anticancer Res. 2019;39:2941-2950.
    PubMed     Text format     Abstract available


  30. HERO T, Buhler H, Kouam PN, Priesch-Grzeszowiak B, et al
    The Triple-negative Breast Cancer Cell Line MDA-MB 231 Is Specifically Inhibited by the Ionophore Salinomycin.
    Anticancer Res. 2019;39:2821-2827.
    PubMed     Text format     Abstract available


  31. RESTREPO DJ, Boczar D, Huayllani MT, Sisti A, et al
    Influence of Race, Income, Insurance, and Education on the Rate of Breast Reconstruction.
    Anticancer Res. 2019;39:2969-2973.
    PubMed     Text format     Abstract available


  32. LINDBLOM EK, Hui S, Brooks J, Dasu A, et al
    Radiation-induced Vascular Damage and the Impact on the Treatment Outcome of Stereotactic Body Radiotherapy.
    Anticancer Res. 2019;39:2721-2727.
    PubMed     Text format     Abstract available


    May 2019
  33. VOGEL C, Malter W, Morgenstern B, Ludwig S, et al
    The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer.
    Anticancer Res. 2019;39:2647-2659.
    PubMed     Text format     Abstract available


  34. TANAKA Y, Kosaka Y, Waraya M, Yokota K, et al
    Differential Prognostic Relevance of Promoter DNA Methylation of CDO1 and HOPX in Primary Breast Cancer.
    Anticancer Res. 2019;39:2289-2298.
    PubMed     Text format     Abstract available


  35. ATIYA HI, Dvorkin-Gheva A, Hassell J, Patel S, et al
    Intraductal Adaptation of the 4T1 Mouse Model of Breast Cancer Reveals Effects of the Epithelial Microenvironment on Tumor Progression and Metastasis.
    Anticancer Res. 2019;39:2277-2287.
    PubMed     Text format     Abstract available


  36. EICHLER C, Schulz C, Thangarajah F, Malter W, et al
    A Retrospective Head-to-head Comparison Between TiLoop Bra/TiMesh(R) and Seragyn(R) in 320 Cases of Reconstructive Breast Surgery.
    Anticancer Res. 2019;39:2599-2605.
    PubMed     Text format     Abstract available


  37. RUSAK A, Jablonska K, Piotrowska A, Grzegrzolka J, et al
    Correlation of Expression of CHI3L1 and Nogo-A and their Role in Angiogenesis in Invasive Ductal Breast Carcinoma.
    Anticancer Res. 2019;39:2341-2350.
    PubMed     Text format     Abstract available


    April 2019
  38. TOKUNAGA S, Takashima T, Kashiwagi S, Noda S, et al
    Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial.
    Anticancer Res. 2019;39:2053-2059.
    PubMed     Text format     Abstract available


  39. LEE SM, Lee KW, Kim MA, Song YS, et al
    Serial Texture Analyses on ADC Maps for Evaluation of Antiangiogenic Therapy in Rat Breast Cancer.
    Anticancer Res. 2019;39:1875-1882.
    PubMed     Text format     Abstract available


  40. ALVES LN, Missailidis S, Lage CAS, DE Almeida CEB, et al
    Anti-MUC1 Aptamer as Carrier Tool of the Potential Radiosensitizer Phenanthroline in MCF-7 Breast Cancer 1,10 Cells.
    Anticancer Res. 2019;39:1859-1867.
    PubMed     Text format     Abstract available


  41. MEGO M, Karaba M, Minarik G, Benca J, et al
    Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
    Anticancer Res. 2019;39:1829-1837.
    PubMed     Text format     Abstract available


  42. PINELLI A, Ferrario P, Trivulzio S
    Preliminary Observation on the Cytotoxic Activity of New Chlorophyllin Derivative RCD on Human Tumour Cell Lines In Vitro.
    Anticancer Res. 2019;39:1807-1812.
    PubMed     Text format     Abstract available


  43. GKANTAIFI A, Papadopoulos C, Spyropoulou D, Toumpourleka M, et al
    Breast Radiotherapy and Early Adverse Cardiac Effects. The Role of Serum Biomarkers and Strain Echocardiography.
    Anticancer Res. 2019;39:1667-1673.
    PubMed     Text format     Abstract available


    March 2019
  44. SHIMAZU K, Miyake T, Okuno J, Naoi Y, et al
    One-step Nucleic Acid Amplification Can Identify Sentinel Node-negative Breast Cancer Patients With Excellent Prognosis.
    Anticancer Res. 2019;39:1447-1454.
    PubMed     Text format     Abstract available


  45. LEWIN NL, Luetragoon T, Andersson BA, Oliva D, et al
    The Influence of Single Nucleotide Polymorphisms and Adjuvant Radiotherapy on Systemic Inflammatory Proteins, Chemokines and Cytokines of Patients With Breast Cancer.
    Anticancer Res. 2019;39:1287-1292.
    PubMed     Text format     Abstract available


  46. VELLANKI SH, Cruz RGB, Richards CE, Smith YE, et al
    Antibiotic Tetrocarcin-A Down-regulates JAM-A, IAPs and Induces Apoptosis in Triple-negative Breast Cancer Models.
    Anticancer Res. 2019;39:1197-1204.
    PubMed     Text format     Abstract available


  47. HANSEN HC, Janssen S, Thieme C, Perlov A, et al
    Potential Impact of the Interval Between Imaging and Whole-brain Radiotherapy in Patients With Relatively Favorable Survival Prognoses.
    Anticancer Res. 2019;39:1343-1346.
    PubMed     Text format     Abstract available


  48. REZNICZEK GA, Grunwald C, Hilal Z, Scheich J, et al
    ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).
    Anticancer Res. 2019;39:1267-1273.
    PubMed     Text format     Abstract available


  49. PAPAIOANNOU E, Sakellakis M, Melachrinou M, Tzoracoleftherakis E, et al
    A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis.
    Anticancer Res. 2019;39:1217-1232.
    PubMed     Text format     Abstract available


    February 2019
  50. SONNENBLICK A, Bailey A, Uziely B, Untch M, et al
    Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial.
    Anticancer Res. 2019;39:797-802.
    PubMed     Text format     Abstract available


  51. LEE SJ, Jeong JH, Lee IH, Lee J, et al
    Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.
    Anticancer Res. 2019;39:751-758.
    PubMed     Text format     Abstract available


  52. SEKI T, Liu J, Brutkiewicz RR, Tsuji M, et al
    A Potent CD1d-binding Glycolipid for iNKT-Cell-based Therapy Against Human Breast Cancer.
    Anticancer Res. 2019;39:549-555.
    PubMed     Text format     Abstract available


  53. MIYAKE T, Kim SJ, Shimoda M, Kagara N, et al
    Diagnostic Utility of Third-Look, Contrast-Enhanced Sonography Followed by Needle Biopsy for MRI, But Not Ultrasonography Breast Lesions.
    Anticancer Res. 2019;39:915-921.
    PubMed     Text format     Abstract available


  54. KOSTRZEWA T, Przychodzen P, Gorska-Ponikowska M, Kuban-Jankowska A, et al
    Curcumin and Cinnamaldehyde as PTP1B Inhibitors With Antidiabetic and Anticancer Potential.
    Anticancer Res. 2019;39:745-749.
    PubMed     Text format     Abstract available


    January 2019
  55. ROINE E, Farkkila N, Sintonen H, Taari K, et al
    Costs in Different States of Breast Cancer.
    Anticancer Res. 2019;39:353-359.
    PubMed     Text format     Abstract available


  56. TAKALA L, Barlund M, Kellokumpu-Lehtinen PL, Pirkko L, et al
    Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer.
    Anticancer Res. 2019;39:279-283.
    PubMed     Text format     Abstract available


  57. FREGATTI P, Gipponi M, Depaoli F, Murelli F, et al
    No Ink on Ductal Carcinoma In Situ: A Single Centre Experience.
    Anticancer Res. 2019;39:459-466.
    PubMed     Text format     Abstract available


  58. BAE GE, Yoon N, Cho EY, Kim HS, et al
    Clinicopathological and Molecular Characteristics of Mammary Adenoid Cystic Carcinoma With Adipocytic Differentiation With Emphasis on the Identification of a Novel BRAF Mutation.
    Anticancer Res. 2019;39:369-374.
    PubMed     Text format     Abstract available


  59. EICHLER C, Fromme J, Thangarajah F, Puppe J, et al
    Gene-expression Profiling - A Decision Impact Analysis: Decision Dependency on Oncotype DX(R) as a Function of Oncological Work Experience in 117 Cases.
    Anticancer Res. 2019;39:297-303.
    PubMed     Text format     Abstract available


    December 2018
  60. RADES D, Panzner A, Janssen S, Dunst J, et al
    Outcomes After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients with Oligo-metastatic Breast Cancer.
    Anticancer Res. 2018;38:6897-6903.
    PubMed     Text format     Abstract available


  61. MANOUCHEHRI JM, Kalafatis M
    Ursolic Acid Promotes the Sensitization of rhTRAIL-resistant Triple-negative Breast Cancer.
    Anticancer Res. 2018;38:6789-6795.
    PubMed     Text format     Abstract available


  62. OLIVA D, Nilsson M, Strandeus M, Andersson BA, et al
    Individual Genetic Variation Might Predict Acute Skin Reactions in Women Undergoing Adjuvant Breast Cancer Radiotherapy.
    Anticancer Res. 2018;38:6763-6770.
    PubMed     Text format     Abstract available


  63. ORSARIA P, Chiaravalloti A, Caredda E, Marchese PV, et al
    Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
    Anticancer Res. 2018;38:6639-6652.
    PubMed     Text format     Abstract available


  64. GERA R, Tayeh S, Chehade HE, Mokbel K, et al
    Does Transdermal Testosterone Increase the Risk of Developing Breast Cancer? A Systematic Review.
    Anticancer Res. 2018;38:6615-6620.
    PubMed     Text format     Abstract available


  65. SHERBET GV, Woo WL, Dlay S
    Application of Artificial Intelligence-based Technology in Cancer Management: A Commentary on the Deployment of Artificial Neural Networks.
    Anticancer Res. 2018;38:6607-6613.
    PubMed     Text format     Abstract available


    November 2018
  66. STEFANOU D, Kokkali S, Tripodaki ES, Drizou M, et al
    Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:6565-6569.
    PubMed     Text format     Abstract available


  67. SAKAGUCHI M, Maebayashi T, Aizawa T, Ishibashi N, et al
    Whole-brain Radiation Therapy for Breast Cancer Patients with Dural Metastasis Without Concomitant Brain Metastasis and Leptomeningeal Metastasis.
    Anticancer Res. 2018;38:6405-6411.
    PubMed     Text format     Abstract available


  68. FU S, Lin J
    Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
    Anticancer Res. 2018;38:6271-6279.
    PubMed     Text format     Abstract available


  69. DU X, Klaschik K, Mallmann P, Isachenko E, et al
    An Experimental Model of Breast Cancer Cells: Informative Protocol for In Vitro Culture.
    Anticancer Res. 2018;38:6237-6245.
    PubMed     Text format     Abstract available


  70. SHI H, Liu J, Tu Y, Freter CE, et al
    Oolong Tea Extract Induces DNA Damage and Cleavage and Inhibits Breast Cancer Cell Growth and Tumorigenesis.
    Anticancer Res. 2018;38:6217-6223.
    PubMed     Text format     Abstract available


  71. TOROPOV AA, Toropova AP
    Predicting Cytotoxicity of 2-Phenylindole Derivatives Against Breast Cancer Cells Using Index of Ideality of Correlation.
    Anticancer Res. 2018;38:6189-6194.
    PubMed     Text format     Abstract available


  72. MUSA MA, Badisa VLD, Latinwo LM, Ntantie E, et al
    7,8-Dihydroxy-3-arylcoumarin Induces Cell Death Through S-Phase Arrest in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2018;38:6091-6098.
    PubMed     Text format     Abstract available


  73. LUCCHETTI J, Formica V, Giuliano G, Coletta D, et al
    Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia.
    Anticancer Res. 2018;38:6561-6564.
    PubMed     Text format     Abstract available


  74. KORDONI M, Rigakos G, Kim YHM, Kaklamanis L, et al
    Atypical Femoral Fractures (AFF) from Bone Remodeling Agents in Patients with Cancer.
    Anticancer Res. 2018;38:6439-6444.
    PubMed     Text format     Abstract available


    October 2018
  75. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
    Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Anticancer Res. 2018;38:6023-6026.
    PubMed     Text format     Abstract available


  76. KONDO Y, Fukuyama T, Yamamura R, Futawatari N, et al
    Detection of KK-LC-1 Protein, a Cancer/Testis Antigen, in Patients with Breast Cancer.
    Anticancer Res. 2018;38:5923-5928.
    PubMed     Text format     Abstract available


  77. DUTTA D, Russell C, Kim J, Chandra S, et al
    Differential Mobility of Breast Cancer Cells and Normal Breast Epithelial Cells Under DC Electrophoresis and Electroosmosis.
    Anticancer Res. 2018;38:5733-5738.
    PubMed     Text format     Abstract available


  78. ICHIHARA H, Okumura M, Tsujimura K, Matsumoto Y, et al
    Theranostics with Hybrid Liposomes in an Orthotopic Graft Model Mice of Breast Cancer.
    Anticancer Res. 2018;38:5645-5654.
    PubMed     Text format     Abstract available


  79. FREEMAN J, Crowley PD, Foley AG, Gallagher HC, et al
    Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery.
    Anticancer Res. 2018;38:5599-5606.
    PubMed     Text format     Abstract available


    September 2018
  80. BONZANO E, Belgioia L, Fregatti P, Friedman D, et al
    Tumor Size-driven Dose of Intraoperative Radiotherapy for Breast Cancer: 18 Gy Versus 21 Gy.
    Anticancer Res. 2018;38:5475-5479.
    PubMed     Text format     Abstract available


  81. NAKATSUKASA K, Ouchi Y, Sakaguchi K, Goto M, et al
    Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
    Anticancer Res. 2018;38:5459-5463.
    PubMed     Text format     Abstract available


  82. JOO JH, Kim SS, Son BH, DO Ahn S, et al
    Evaluation of the Prognostic Stage in the 8th Edition of the American Joint Committee on Cancer in Patients with Breast Cancer and Internal Mammary Lymph Node Metastasis.
    Anticancer Res. 2018;38:5357-5361.
    PubMed     Text format     Abstract available


  83. ZHOU M, Peddi P, Chu QD
    Radiation Therapy for Positive Surgical Margins in Women >/=70 Years with Stage I, Estrogen Receptor-positive Breast Cancer.
    Anticancer Res. 2018;38:5253-5260.
    PubMed     Text format     Abstract available


  84. WILHELM CA, Clor ZJ, Kelts JL
    Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:5043-5048.
    PubMed     Text format     Abstract available


  85. LEBLANC N, Harquail J, Crapoulet N, Ouellette RJ, et al
    Pax-5 Inhibits Breast Cancer Proliferation Through MiR-215 Up-regulation.
    Anticancer Res. 2018;38:5013-5026.
    PubMed     Text format     Abstract available


  86. PARK HL, Pyo YC, Kim KY, Park JS, et al
    Recurrence Rates and Characteristics of Phyllodes Tumors Diagnosed by Ultrasound-guided Vacuum-assisted Breast Biopsy (VABB).
    Anticancer Res. 2018;38:5481-5487.
    PubMed     Text format     Abstract available


    August 2018
  87. FUJII T, Yanai K, Tokuda S, Nakazawa Y, et al
    Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer.
    Anticancer Res. 2018;38:4927-4931.
    PubMed     Text format     Abstract available


  88. ROSSI L, Biagioni C, McCartney A, Moretti E, et al
    Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.
    Anticancer Res. 2018;38:4839-4845.
    PubMed     Text format     Abstract available


  89. MOKBEL K, Wazir U, Wazir A, Kasem A, et al
    The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER(+)/HER2(-) Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic Index.
    Anticancer Res. 2018;38:4747-4752.
    PubMed     Text format     Abstract available


  90. FERRONI P, Roselli M, Buonomo OC, Spila A, et al
    Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer.
    Anticancer Res. 2018;38:4705-4712.
    PubMed     Text format     Abstract available


  91. WINSKA P, Skierka K, Lukowska-Chojnacka E, Koronkiewicz M, et al
    Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
    Anticancer Res. 2018;38:4617-4627.
    PubMed     Text format     Abstract available


  92. YEH MH, Tzeng YJ, Fu TY, You JJ, et al
    Extracellular Matrix-receptor Interaction Signaling Genes Associated with Inferior Breast Cancer Survival.
    Anticancer Res. 2018;38:4593-4605.
    PubMed     Text format     Abstract available


  93. RABACOW APM, Meza A, DE Oliveira EJT, DE David N, et al
    Evaluation of the Antitumor Potential of the Resorcinolic Lipid 3-Heptyl-3,4,6-trimethoxy-3H-isobenzofuran-1-one in Breast Cancer Cells.
    Anticancer Res. 2018;38:4565-4576.
    PubMed     Text format     Abstract available


  94. KENAN ES, Friger M, Shochat-Bigon D, Schayek H, et al
    Accuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in Israel.
    Anticancer Res. 2018;38:4557-4563.
    PubMed     Text format     Abstract available


  95. MASUDA T, Shinden Y, Noda M, Ueo H, et al
    Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer.
    Anticancer Res. 2018;38:4515-4523.
    PubMed     Text format     Abstract available


  96. BOMMAREDDY A, Knapp AWK, Nemeth A, Steigerwalt J, et al
    Alpha-Santalol, a Component of Sandalwood Oil Inhibits Migration of Breast Cancer Cells by Targeting the beta-catenin Pathway.
    Anticancer Res. 2018;38:4475-4480.
    PubMed     Text format     Abstract available


  97. HUNKE M, Martinez W, Kashyap A, Bokoskie T, et al
    Antineoplastic Actions of Cinnamic Acids and Their Dimers in Breast Cancer Cells: A Comparative Study.
    Anticancer Res. 2018;38:4469-4474.
    PubMed     Text format     Abstract available


  98. ANDING AL, Jones JD, Newton MA, Curley RW Jr, et al
    4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
    Anticancer Res. 2018;38:4403-4416.
    PubMed     Text format     Abstract available


  99. CAZZANIGA M, Bonanni B
    Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?
    Anticancer Res. 2018;38:4393-4402.
    PubMed     Text format     Abstract available


  100. SPRAVE T, Verma V, Forster R, Schlampp I, et al
    Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial.
    Anticancer Res. 2018;38:4961-4968.
    PubMed     Text format     Abstract available


  101. HUANG FJ, Hung CC, Chang CW, Chao JH, et al
    Evaluation of Injectable Chitosan-based Co-cross-linking Hydrogel for Local Delivery of (188)Re-LIPO-DOX to Breast-tumor-bearing Mouse Model.
    Anticancer Res. 2018;38:4651-4659.
    PubMed     Text format     Abstract available


  102. EMMANUEL N, Lofgren KA, Peterson EA, Meier DR, et al
    Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells.
    Anticancer Res. 2018;38:4435-4441.
    PubMed     Text format     Abstract available


    July 2018
  103. MORI H, Kubo M, Kai M, Kurata K, et al
    Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.
    Anticancer Res. 2018;38:4381-4386.
    PubMed     Text format     Abstract available


  104. TANAKA T, Uchida H
    Inhibition of Survivin by Adenovirus Vector Enhanced Paclitaxel-induced Apoptosis in Breast Cancer Cells.
    Anticancer Res. 2018;38:4281-4288.
    PubMed     Text format     Abstract available


  105. KUBO M, Umebayashi M, Kurata K, Mori H, et al
    Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:4273-4279.
    PubMed     Text format     Abstract available


  106. SAKAGUCHI K, Nakatsukasa K, Koyama H, Kato M, et al
    Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:4073-4081.
    PubMed     Text format     Abstract available


  107. CHIANG KC, Yeh CN, Yeh TS, Juang HH, et al
    MART-10, a 1alpha,25(OH)2D3 Analog, Potently Represses Metastasis of ER(+) Breast Cancer Cells with VEGF-A Overexpression.
    Anticancer Res. 2018;38:3879-3887.
    PubMed     Text format     Abstract available


  108. TORATA N, Kubo M, Miura D, Ohuchida K, et al
    Visualizing Energy Charge in Breast Carcinoma Tissues by MALDI Mass-spectrometry Imaging Profiles of Low-molecular-weight Metabolites.
    Anticancer Res. 2018;38:4267-4272.
    PubMed     Text format     Abstract available


  109. FERDOVA E, Baxa J, Narsanska A, Hes O, et al
    Low-dose High-resolution (18)F-FDG-PET/CT Using Time-of-flight and Point-spread Function Reconstructions: A Role in the Detection of Breast Carcinoma Axillary Lymph Node Metastases.
    Anticancer Res. 2018;38:4145-4148.
    PubMed     Text format     Abstract available


  110. GRUBER I, Henzel M, Schonfisch B, Stabler A, et al
    Prediction of Non-sentinel Lymph Node Metastases After Positive Sentinel Lymph Nodes Using Nomograms.
    Anticancer Res. 2018;38:4047-4056.
    PubMed     Text format     Abstract available


    June 2018
  111. MALTER W, Hellmich M, Badian M, Kirn V, et al
    Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
    Anticancer Res. 2018;38:3657-3662.
    PubMed     Text format     Abstract available


  112. TRESKA V, Topolcan O, Zoubkova V, Treskova I, et al
    Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases.
    Anticancer Res. 2018;38:3647-3652.
    PubMed     Text format     Abstract available


  113. LI J, Zhang J, Jin L, Deng H, et al
    Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway.
    Anticancer Res. 2018;38:3427-3434.
    PubMed     Text format     Abstract available


  114. CHOE MH, Kim J, Ahn J, Hwang SG, et al
    Centrosome Clustering Is a Tumor-selective Target for the Improvement of Radiotherapy in Breast Cancer Cells.
    Anticancer Res. 2018;38:3393-3400.
    PubMed     Text format     Abstract available


  115. DANDAMUDI A, Tommie J, Nommsen-Rivers L, Couch S, et al
    Dietary Patterns and Breast Cancer Risk: A Systematic Review.
    Anticancer Res. 2018;38:3209-3222.
    PubMed     Text format     Abstract available


  116. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Text format     Abstract available


  117. RUSAK A, Jablonska K, Piotrowska A, Grzegrzolka J, et al
    The Role of CHI3L1 Expression in Angiogenesis in Invasive Ductal Breast Carcinoma.
    Anticancer Res. 2018;38:3357-3366.
    PubMed     Text format     Abstract available


    May 2018
  118. CHANG J, Charalel R, Noda C, Ramaswamy R, et al
    Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization.
    Anticancer Res. 2018;38:3063-3068.
    PubMed     Text format     Abstract available


  119. LUMACHI F, Basso SMM, Camozzi V, Spaziante R, et al
    Bone Mineral Density as a Potential Predictive Factor for Luminal-type Breast Cancer in Postmenopausal Women.
    Anticancer Res. 2018;38:3049-3054.
    PubMed     Text format     Abstract available


  120. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
    Anticancer Res. 2018;38:2929-2938.
    PubMed     Text format     Abstract available


  121. KORONOWICZ AA, Drozdowska M, Banks P, Piasna-Slupecka E, et al
    Fatty Acids of CLA-enriched Egg Yolks Can Induce Mitochondrial Pathway of Apoptosis in MCF-7 Breast Cancer Cells.
    Anticancer Res. 2018;38:2861-2870.
    PubMed     Text format     Abstract available


  122. MINAFRA L, Bravata V, Cammarata FP, Russo G, et al
    Radiation Gene-expression Signatures in Primary Breast Cancer Cells.
    Anticancer Res. 2018;38:2707-2715.
    PubMed     Text format     Abstract available


  123. REINHARDT A, Liu H, Ma Y, Zhou Y, et al
    Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.
    Anticancer Res. 2018;38:2669-2682.
    PubMed     Text format     Abstract available


  124. TUNGSUKRUTHAI S, Petpiroon N, Chanvorachote P
    Molecular Mechanisms of Breast Cancer Metastasis and Potential Anti-metastatic Compounds.
    Anticancer Res. 2018;38:2607-2618.
    PubMed     Text format     Abstract available


  125. LEHMANN-CHE J, Miquel C, Wong J, Callens C, et al
    First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.
    Anticancer Res. 2018;38:2909-2914.
    PubMed     Text format     Abstract available


  126. LIU LC, Wu YC, Kuo SC, Ho CT, et al
    2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells.
    Anticancer Res. 2018;38:2849-2859.
    PubMed     Text format     Abstract available


  127. TATARA T, Mukohara T, Tanaka R, Shimono Y, et al
    3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.
    Anticancer Res. 2018;38:2831-2839.
    PubMed     Text format     Abstract available


  128. OKARVI SM, Aljammaz I
    Preparation and In Vitro and In Vivo Characterization of the Tumor-specific Antigen-derived Peptide as a Potential Candidate for Targeting Human Epidermal Growth Factor Receptor 2-positive Breast Carcinomas.
    Anticancer Res. 2018;38:2823-2830.
    PubMed     Text format     Abstract available


    April 2018
  129. INOUE Y, Yamashita N, Ueo H, Tanaka K, et al
    The Clinical Usefulness of the LigaSure Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer.
    Anticancer Res. 2018;38:2359-2362.
    PubMed     Text format     Abstract available


  130. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Anticancer Res. 2018;38:2311-2321.
    PubMed     Text format     Abstract available


  131. TAKADA K, Kashiwagi S, Goto W, Asano Y, et al
    Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:2285-2294.
    PubMed     Text format     Abstract available


  132. TUOHINEN SS, Keski-Pukkila K, Skytta T, Huhtala H, et al
    Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer.
    Anticancer Res. 2018;38:2207-2215.
    PubMed     Text format     Abstract available


  133. HSIAO CL, Liu LC, Shih TC, Chuang CL, et al
    The Association of Matrix Metalloproteinase-8 Promoter Genotypes in Breast Cancer.
    Anticancer Res. 2018;38:2181-2185.
    PubMed     Text format     Abstract available


  134. ORSARIA P, Caredda E, Genova F, Materazzo M, et al
    Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
    Anticancer Res. 2018;38:2109-2117.
    PubMed     Text format     Abstract available


  135. UEMATSU N, Zhao Y, Kiyomi A, Yuan BO, et al
    Chemo-sensitivity of Two-dimensional Monolayer and Three-dimensional Spheroid of Breast Cancer MCF-7 Cells to Daunorubicin, Docetaxel, and Arsenic Disulfide.
    Anticancer Res. 2018;38:2101-2108.
    PubMed     Text format     Abstract available


  136. JUZENIENE A, Bernoulli J, Suominen M, Halleen J, et al
    Antitumor Activity of Novel Bone-seeking, alpha-emitting (224)Ra-solution in a Breast Cancer Skeletal Metastases Model.
    Anticancer Res. 2018;38:1947-1955.
    PubMed     Text format     Abstract available


  137. PARK HL, Kim KY, Park JS, Shin JE, et al
    Clinicopathological Analysis of Ultrasound-guided Vacuum-assisted Breast Biopsy for the Diagnosis and Treatment of Breast Disease.
    Anticancer Res. 2018;38:2455-2462.
    PubMed     Text format     Abstract available


  138. YU JK, Yue CH, Pan YR, Chiu YW, et al
    Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition via Down-regulation of EGFR Pathway in MDA-MB-231 cells.
    Anticancer Res. 2018;38:2127-2135.
    PubMed     Text format     Abstract available


  139. LITWIN M, Szczepanska-Buda A, Michalowska D, Grzegrzolka J, et al
    Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance in Ductal Breast Carcinoma.
    Anticancer Res. 2018;38:2021-2030.
    PubMed     Text format     Abstract available


  140. NIEMIEC J, Adamczyk A, Harazin-Lechowska A, Ambicka A, et al
    Podoplanin-positive Cancer-associated Stromal Fibroblasts in Primary Tumor and Synchronous Lymph Node Metastases of HER2-overexpressing Breast Carcinomas.
    Anticancer Res. 2018;38:1957-1965.
    PubMed     Text format     Abstract available


    March 2018
  141. GOMES I, Miranda A, Nunes C
    Spatiotemporal Analysis of Breast Cancer Incidence: A Study in Southern Portugal Between 2005 and 2012.
    Anticancer Res. 2018;38:1797-1805.
    PubMed     Text format     Abstract available


  142. ALEXOPOULOU E, Katsila T, Tolia M, Tsoukalas N, et al
    An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients.
    Anticancer Res. 2018;38:1615-1622.
    PubMed     Text format     Abstract available


  143. FRITZ P, Dippon J, Muller S, Goletz S, et al
    Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem.
    Anticancer Res. 2018;38:1585-1593.
    PubMed     Text format     Abstract available


  144. KOI Y, Koga C, Akiyoshi S, Masuda T, et al
    Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
    Anticancer Res. 2018;38:1579-1584.
    PubMed     Text format     Abstract available


  145. DIMAS DT, Perlepe CD, Sergentanis TN, Misitzis I, et al
    The Prognostic Significance of Hsp70/Hsp90 Expression in Breast Cancer: A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:1551-1562.
    PubMed     Text format     Abstract available


  146. DE CREMOUX P, Hamy AS, Lehmann-Che J, Scott V, et al
    COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
    Anticancer Res. 2018;38:1485-1490.
    PubMed     Text format     Abstract available


  147. HA GH, Kim DY, Breuer EK, Kim CK, et al
    Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Anticancer Res. 2018;38:1303-1310.
    PubMed     Text format     Abstract available


  148. UJHELYI M, Pukancsik D, Kelemen P, Kovacs E, et al
    Barriers to Organized Mammography Screening Programs in Hungary: A Questionnaire-based Study of 3,313 Women.
    Anticancer Res. 2018;38:1727-1734.
    PubMed     Text format     Abstract available


  149. EL HAGE CHEHADE H, Mokbel K
    Is Adjuvant Endocrine Therapy Indicated for DCIS Patients After Complete Surgical Excision?
    Anticancer Res. 2018;38:1263-1266.
    PubMed     Text format     Abstract available


    February 2018
  150. FRIEDRICH M, Reichert K, Woeste A, Polack S, et al
    Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:1201-1207.
    PubMed     Text format     Abstract available


  151. FUJII T, Horiguchi J, Yanagita Y, Koibuchi Y, et al
    Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
    Anticancer Res. 2018;38:905-909.
    PubMed     Text format     Abstract available


  152. NAWA-NISHIGAKI M, Kobayashi R, Suzuki A, Hirose C, et al
    Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Anticancer Res. 2018;38:877-884.
    PubMed     Text format     Abstract available


  153. GERA R, Mokbel R, Igor I, Mokbel K, et al
    Does the Use of Hair Dyes Increase the Risk of Developing Breast Cancer? A Meta-analysis and Review of the Literature.
    Anticancer Res. 2018;38:707-716.
    PubMed     Text format     Abstract available


  154. BELKACEMI L, Atkins JL, Yang LU, Gadgil P, et al
    Phosphaplatin Anti-tumor Effect Enhanced by Liposomes Partly via an Up-regulation of PEDF in Breast Cancer.
    Anticancer Res. 2018;38:623-646.
    PubMed     Text format     Abstract available


  155. LUCZYNSKA E, Niemiec J, Heinze S, Adamczyk A, et al
    Intensity and Pattern of Enhancement on CESM: Prognostic Significance and its Relation to Expression of Podoplanin in Tumor Stroma - A Preliminary Report.
    Anticancer Res. 2018;38:1085-1095.
    PubMed     Text format     Abstract available


  156. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Text format     Abstract available


    January 2018
  157. SVOBODOVA S, Kucera R, Fiala O, Marie K, et al
    CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.
    Anticancer Res. 2018;38:465-469.
    PubMed     Text format     Abstract available


  158. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
    Anticancer Res. 2018;38:401-410.
    PubMed     Text format     Abstract available


  159. TAKASHIMA T, Kawajiri H, Nishimori T, Tei S, et al
    Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2018;38:379-383.
    PubMed     Text format     Abstract available


  160. CHAMARAUX-TRAN TN, Mathelin C, Aprahamian M, Joshi GP, et al
    Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial.
    Anticancer Res. 2018;38:95-105.
    PubMed     Text format     Abstract available


  161. JARDEL P, Vignot S, Cutuli B, Creisson A, et al
    Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review.
    Anticancer Res. 2018;38:23-31.
    PubMed     Text format     Abstract available


    December 2017
  162. PESSINA F, Navarria P, Cozzi L, Franceschini D, et al
    Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis.
    Anticancer Res. 2017;37:7057-7062.
    PubMed     Text format     Abstract available


  163. YAMANOUCHI K, Kuba S, Sakimura C, Morita M, et al
    The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer.
    Anticancer Res. 2017;37:6947-6951.
    PubMed     Text format     Abstract available


  164. MOKBEL K, Wazir U, El Hage Chehade H, Manson A, et al
    A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer.
    Anticancer Res. 2017;37:6863-6869.
    PubMed     Text format     Abstract available


  165. NIMEUS E, Folkesson E, Nodin B, Hartman L, et al
    Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
    Anticancer Res. 2017;37:6845-6853.
    PubMed     Text format     Abstract available


  166. AULA H, Skytta T, Tuohinen S, Luukkaala T, et al
    Adjuvant Breast Cancer Treatments Induce Changes in Homoarginine Level - A Prospective Observational Study.
    Anticancer Res. 2017;37:6815-6824.
    PubMed     Text format     Abstract available


  167. PEREIRA MC, Mohammed R, VAN Otterlo WAL, DE Koning CB, et al
    Evaluation of the Effects of Aminonaphthoquinone Derivatives in Combination with Curcumin Against ER-positive Breast Cancer and Related Tumours.
    Anticancer Res. 2017;37:6749-6759.
    PubMed     Text format     Abstract available


  168. STOPE MB, Weiss M, Koensgen D, Popp SL, et al
    Y-box Binding Protein-1 Enhances Oncogenic Transforming Growth Factor beta Signaling in Breast Cancer Cells via Triggering Phospho-Activation of Smad2.
    Anticancer Res. 2017;37:6745-6748.
    PubMed     Text format     Abstract available


  169. MATSUI C, Takatani-Nakase T, Maeda S, Nakase I, et al
    Potential Roles of GLUT12 for Glucose Sensing and Cellular Migration in MCF-7 Human Breast Cancer Cells Under High Glucose Conditions.
    Anticancer Res. 2017;37:6715-6722.
    PubMed     Text format     Abstract available


  170. KAR A, Liu B, Gutierrez-Hartmann A
    ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2(+) Breast Cancer Cells.
    Anticancer Res. 2017;37:6583-6591.
    PubMed     Text format     Abstract available


  171. SPARTALIS E, Tsilimigras DI, Charalampoudis P, Karachaliou GS, et al
    The "Yin and Yang" of Platelet-rich Plasma in Breast Reconstruction After Mastectomy or Lumpectomy for Breast Cancer.
    Anticancer Res. 2017;37:6557-6562.
    PubMed     Text format     Abstract available


  172. MIRKA H, Tupy R, Narsanska A, Hes O, et al
    Pre-surgical Multiparametric Assessment of Breast Lesions Using 3-Tesla Magnetic Resonance.
    Anticancer Res. 2017;37:6965-6970.
    PubMed     Text format     Abstract available


  173. SAPINHO G, Alho I, Bicho M, Coelho C, et al
    Total Knockdown of LMW-PTP in MDA-MB-231 Cells Reduces Osteoclastogenesis.
    Anticancer Res. 2017;37:6671-6677.
    PubMed     Text format     Abstract available


  174. MANOUCHEHRI JM, Kalafatis M
    Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment.
    Anticancer Res. 2017;37:6593-6599.
    PubMed     Text format     Abstract available


  175. CHRISTOPOULOS PF, Vlachogiannis NI, Vogkou CT, Koutsilieris M, et al
    The Role of the Androgen Receptor Signaling in Breast Malignancies.
    Anticancer Res. 2017;37:6533-6540.
    PubMed     Text format     Abstract available


    November 2017
  176. MATSUI A, Tatibana A, Suzuki N, Hirata M, et al
    Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.
    Anticancer Res. 2017;37:6481-6488.
    PubMed     Text format     Abstract available


  177. SHEIKH IA, Jiffri EH, Kamal MA, Ashraf GM, et al
    Lactoperoxidase, an Antimicrobial Milk Protein, as a Potential Activator of Carcinogenic Heterocyclic Amines in Breast Cancer.
    Anticancer Res. 2017;37:6415-6420.
    PubMed     Text format     Abstract available


  178. SHEIKH IA, Beg MA, Yasir M
    Molecular Interactions of Carcinogenic Aromatic Amines, 4-Aminobiphenyl and 4,4'-Diaminobiphenyl, with Lactoperoxidase - Insight to Breast Cancer.
    Anticancer Res. 2017;37:6245-6249.
    PubMed     Text format     Abstract available


  179. JEON D, Kim H, Nam K, Oh S, et al
    Cytotoxic Effect of Nano-SiO2 in Human Breast Cancer Cells via Modulation of EGFR Signaling Cascades.
    Anticancer Res. 2017;37:6189-6197.
    PubMed     Text format     Abstract available


  180. WAKIMOTO R, Ono M, Takeshima M, Higuchi T, et al
    Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells.
    Anticancer Res. 2017;37:6153-6159.
    PubMed     Text format     Abstract available


  181. DU J, Sun Y, Lu YY, Lau E, et al
    Berberine and Evodiamine Act Synergistically Against Human Breast Cancer MCF-7 Cells by Inducing Cell Cycle Arrest and Apoptosis.
    Anticancer Res. 2017;37:6141-6151.
    PubMed     Text format     Abstract available


    October 2017
  182. SHOJI F, Yamashita N, Inoue Y, Kozuma Y, et al
    Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Anticancer Res. 2017;37:5871-5876.
    PubMed     Text format     Abstract available


  183. KARMAKAR MK, Samy W, Lee A, Li JW, et al
    Survival Analysis of Patients with Breast Cancer Undergoing a Modified Radical Mastectomy With or Without a Thoracic Paravertebral Block: a 5-Year Follow-up of a Randomized Controlled Trial.
    Anticancer Res. 2017;37:5813-5820.
    PubMed     Text format     Abstract available


  184. HE K, Wang X, Guan X, Yu Q, et al
    Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.
    Anticancer Res. 2017;37:5647-5653.
    PubMed     Text format     Abstract available


  185. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
    Anticancer Res. 2017;37:5623-5630.
    PubMed     Text format     Abstract available


  186. CHU QD, Zhou M, Medeiros KL, Peddi P, et al
    Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (>/=70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
    Anticancer Res. 2017;37:5585-5594.
    PubMed     Text format     Abstract available


  187. PHAM DH, Kim JS, Kim SK, Shin DJ, et al
    Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro.
    Anticancer Res. 2017;37:5507-5513.
    PubMed     Text format     Abstract available


  188. BOBIN-DUBIGEON C, Chauvin A, Brillaud-Meflah V, Boiffard F, et al
    Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity.
    Anticancer Res. 2017;37:5495-5498.
    PubMed     Text format     Abstract available


  189. CALIS IU, Cosan DT, Mutlu F
    Effects of S1P1 and S1P3 in ER+ and ER- Breast Cancer Cells.
    Anticancer Res. 2017;37:5469-5475.
    PubMed     Text format     Abstract available


  190. GIGLI S, Amabile MI, DI Pastena F, DE Luca A, et al
    Lipofilling Outcomes Mimicking Breast Cancer Recurrence: Case Report and Update of the Literature.
    Anticancer Res. 2017;37:5395-5398.
    PubMed     Text format     Abstract available


  191. HARUNA F, Lipsett A, Marignol L
    Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2017;37:5343-5353.
    PubMed     Text format     Abstract available


  192. GLASSMAN D, Hignett S, Rehman S, Linforth R, et al
    Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.
    Anticancer Res. 2017;37:5329-5341.
    PubMed     Text format     Abstract available


  193. GRZEGRZOLKA J, Wojtyra P, Biala M, Piotrowska A, et al
    Correlation Between Expression of Twist and Podoplanin in Ductal Breast Carcinoma.
    Anticancer Res. 2017;37:5485-5493.
    PubMed     Text format     Abstract available


    September 2017
  194. ISHITOBI M, Fukui R, Hashimoto Y, Kittaka N, et al
    Safety for Repeat Lumpectomy Without Radiotherapy for Ipsilateral Breast Tumor Recurrence.
    Anticancer Res. 2017;37:5293-5299.
    PubMed     Text format     Abstract available


  195. EICHLER C, Abrar S, Puppe J, Arndt M, et al
    Detection of Ductal Carcinoma In Situ by Ultrasound and Mammography: Size-dependent Inaccuracy.
    Anticancer Res. 2017;37:5065-5070.
    PubMed     Text format     Abstract available


  196. FUJII T, Yanai K, Tokuda S, Nakazawa Y, et al
    Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings.
    Anticancer Res. 2017;37:5053-5056.
    PubMed     Text format     Abstract available


  197. UEHARA S, Saito K, Asami H, Ohta Y, et al
    Role of ARHGAP24 in ADP Ribosylation Factor 6 (ARF6)-dependent Pseudopod Formation in Human Breast Carcinoma Cells.
    Anticancer Res. 2017;37:4837-4844.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: